Novo Nordisk files reply in support of motion to dismiss Prandin antitrust case
MLex Summary: Novo Nordisk has filed a reply in support of its motion to dismiss a complaint alleging that it delayed the entry of a generic version of its diabetes drug Prandin into the...To view the full article, register now.
Already a subscriber? Click here to view full article